The Minnesota Partnership for Biotechnology and Medical Genomics was formed in 2003 as a unique collaborative venture among Mayo Clinic, University of Minnesota, and State of Minnesota. The idea was born out of a desire to elevate Minnesota’s position in the area of bioscience research.
When Minnesota leaders created the Partnership they set the goal of positioning Minnesota as a world leader in biotechnology and biomedical research to improve health and save lives while offering economic advantages to Minnesota. The collaboration has become a globally- recognized model of innovation in the biomedical field.
The Partnership is focused on the following goals:
- Position Minnesota as a world leader in biotechnology and medical genomics
- Conduct powerful research to improve life and stimulate Minnesota’s economy
- Achieve breakthroughs in new methods to accurately diagnose and develop innovative therapies for major disease areas
- Create a pipeline for new industry – dynamic new businesses and quality jobs
- Maintain Minnesota’s position as a destination for medical care and a leader in the medical industry
The Partnership seeks to generate benefits on two primary fronts:
- Improve health through development of diagnostics and treatments for multiple high-profile diseases.
- Economic opportunity for Minnesota through an enhanced research and development base and commercialization of biomedical innovations.